Progesterone receptors - animal models and cell signalling in breast cancer: Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer by Lanari, Claudia & Molinolo, Alfredo A
240 ER = estrogen receptor; MAPK = mitogen activating protein kinase; MPA = medroxyprogesterone acetate; PR = progesterone receptor.
Breast Cancer Research    Vol 4 No 6 Lanari and Molinolo
Introduction
Progesterone and estradiol, and their cognate receptors,
play essential roles in systems as diverse as the reproduc-
tive tract, the mammary gland and the nervous system. The
best understood role of ovarian steroid hormones is prob-
ably their participation in reproductive tract physiology.
Estrogens drive the proliferation of the endometrium after
menses, and induce progesterone receptor (PR) expres-
sion, whereas progesterone plays a role in proliferation,
differentiation and maintenance of the endometrial epithe-
lium and stroma in preparation for implantation.
The classic view (namely, estrogens = proliferation and
progestins = differentiation) has been extrapolated to
systems other than the endometrium, such as the
mammary gland, and has probably contributed to a long-
held belief that estrogens are the main steroid hormones
implicated in the induction of breast cancer. However, this
concept has been challenged by growing experimental
evidence in rodents. This evidence points towards proges-
terone and its related signaling pathways as important
players in the induction, progression and maintenance of
the neoplastic phenotype in the mammary gland [1]. More-
over, recently available clinical data demonstrate a higher
risk of breast cancer in patients under hormone replace-
ment therapy using a combination of estrogens and prog-
estins, as compared with those using estrogens alone
[2,3]. The PR has emerged as a major player in the field of
breast cancer.
As with the estrogen receptor (ER) signaling pathway,
blocking the progesterone/PR system, alone or in combi-
nation with other treatment modalities, has arisen as a
logical therapeutic possibility in breast cancer [4].
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PR signaling in breast cancer development:
experimental support
In vivo studies
We demonstrated in 1986 [5] that, in BALB/c female
mice, medroxyprogesterone acetate (MPA) alone induces
mammary carcinomas that expresses PRs and ERs, that
are hormone dependent and that, unlike what happens in
most other experimental models of breast cancer, originate
axillary and lung metastases [6,7]. This was the first, and as
far as we know the only, time that a progestin alone was
demonstrated to induce hormone-dependent mammary
cancer. No tumors were observed in untreated controls or
in virgin female BALB/c mice of our colony. Some of these
tumors have been maintained by subcutaneous passages
and they still maintain the steroid receptor expression.
At about the same time, Nagasawa et al. [8] showed that
MPA enhanced spontaneous mammary tumorigenesis in
SHN mice, but they did not report on steroid receptor
expression or hormone sensitivity. In 1993, we were able
to induce mammary carcinomas in BALB/c female mice
using progesterone [9]. Most of the tumors were lobular in
morphology and they progressively ceased to express
receptors after a few in vivo passages. In mice, progestins
can act as co-carcinogens together with chemical initia-
tors, such as N-methyl-N-nitrosourea [10] and dimethyl-
benzanthracene [11]. Recent studies in PR knockout mice
confirmed the role of PR on dimethylbenzanthracene-
induced tumorigenesis [12]. There is evidence in rats that,
depending on the time of carcinogen administration in
relation to hormone treatment, progesterone can act as a
promoter [13].
In vitro studies
Progestins have been demonstrated to exert variable
effects on different cell types depending on environmental
factors and culture conditions. Progesterone increases
DNA synthesis in mouse mammary gland organ culture,
decreases proliferation in primary cultures of normal
human breast epithelium and cultured breast cancer cells,
increases cell proliferation under certain experimental con-
ditions in T47-D cells [14] and increases cell proliferation
in primary cultures of experimental mouse mammary
tumors [15].
Dissecting the PR signaling pathway
Progesterone action in the target cell
The physiological effects of progesterone are mediated by
specific intracellular proteins known as PRs. In rodents
and humans, the PR gene encodes two proteins termed
PRA and PRB. Both isoforms are the result of transcription
of two alternative promoters and initiation of translation at
two different AUG codons. Their physiological roles are
different according to their structural and functional prop-
erties. PRA and PRB may activate different genes, and their
ratio of expression may be important in cell fate [16,17].
Activated PRs would recruit a series of important regula-
tory proteins, which can serve as coactivators or corepres-
sors, such as SRC-1, SRC-2 and SRC-3, CBP/p300 and
others. These coregulatory proteins may modulate histone
acetylation/deacetylation and chromatin remodeling, and
may have additional effects [18]. The PR complex will bind
a specific DNA sequence, the progesterone-responsive
element, and will initiate the transcription of target genes.
A complete review of the classical mechanism by which
PRs are activated by their natural ligands is beyond the
scope of the present review, and has been extensively
described elsewhere [19]. Such a complex activation
sequence offers several steps in which other regulatory
mechanisms of the progesterone signaling pathway can
be integrated.
PR activation
Four sites of the PR are basally phosphorylated in humans
(Ser 81, Ser 162, Ser 190 and Ser 400), and exhibit a
rapid twofold increase on hormone treatment. The other
sites (Ser 102, Ser 294 and Ser 345) are hormone
inducible, and 1–2 hours of treatment are required to
reach maximal phosphorylation. Their different kinetics in
response to hormone suggests that these two groups of
phosphorylation sites are targets of different signaling
pathways and kinases, and serve distinct functional struc-
tural roles. Phosphorylation may not serve as a regulatory
on–off switch for transcriptional activity, but rather func-
tions to either amplify or attenuate activity [20].
Several crosstalk mechanisms involving the conventional
nuclear PR pathway with different growth factors, neuro-
transmitters and polypeptide hormones have been
described. Most studies indicate that progestins upregu-
late growth factor and cytokine receptors at the cell
surface. They also act at the cytoplasmic level to regulate
several intracellular effectors by increasing the levels and
altering the subcellular compartmentalization of, for
example, Stat 5, and by potentiating mitogen-activated
protein kinase (MAPK) and Janus kinase activities [14]. In
addition, at the nuclear level, growth factor-regulated
nuclear transcription factors may synergize with agonist-
occupied PRs to modulate the activity of key genes
involved in breast cancer fate [14]. All these studies deal
with increases in sensitivity to different proliferative
signals, rather than a ligand-independent interaction with
PRs. Evidence of a direct PR activation by the protein
kinase A pathway was provided by Edwards et al. [21] in
the T-47D cell line. Recently, Jacobsen et al. [22] studied
ligand-independent activation of the PRA, which resulted
in increased expression of several genes, among them
prolactin receptors.
In a nonengineered system, we have provided evidence of
crosstalk between the PR and basic fibroblast growth
factor using primary cultures of MPA-induced mammary242
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carcinomas. The stimulatory effect of MPA could be mim-
icked by basic fibroblast growth factor [15], and these
effects could be blocked by antiprogestins or by PR anti-
sense oligonucleotides. This indicates that fibroblast
growth factors, which act by activation of MAPK, may also
use the PR pathway to induce cell proliferation. These
results are also supported by data from Elizalde et al. [23],
who recently demonstrated that heregulin, which also acti-
vates MAPK, is able to induce PR mobility gel shift or to
activate luciferase in C4-HD cells, a MPA-responsive
tumor line transfected with a progesterone-responsive
element luciferase reporter gene.
Steroid receptors may crosstalk with each other. Migliac-
cio et al. [24] described an interaction between PRB,
ERα and Src at the cell membrane level, which would
be necessary for steroid-induced S-phase entry of cells.
PR nongenomic mechanisms of action have been
described in different systems [25], but not yet in the
mammary gland.
All studies regarding crosstalks and PRs in the mammary
gland were performed in vitro. In vivo demonstration of
these mechanisms will strengthen the role of the PR on
mammary gland or breast cancer proliferation.
Antiprogestins: experimental and clinical
studies
Mifepristone demonstrated dose-dependent growth
inhibitory effects in vitro in PR-positive human breast
cancer cell lines, and its antiproliferative effects were
evident even in the total absence of estrogens [26]. We
were able to demonstrate complete regression of experi-
mental MPA-induced metastatic tumors with antiprog-
estins  in vivo [27]. Additive antitumor effects using
onapristone in combination with tamoxifen or the pure
antiestrogen ICI 164384 have been demonstrated in
several experimental models [28].
In clinical studies, from 169 patients treated, a complete
response was observed in only one patient, and partial
response rates varied between 11 and 56% [4]. Interest-
ingly, patients resistant to treatment with tamoxifen or
high-dose progestins responded to antiprogestins. All clin-
ical trials have been carried out in patients with advanced
disease, who had frequently become resistant to other
endocrine therapies.
Conclusions and perspectives
One treatment modality capable of curing breast cancer
is still wishful thinking; however, the use of combined
modalities is more realistic. The effects by which the
progesterone/PR signaling pathway can be modulated
are many, and the reviewed evidence from both experi-
mental results and clinical trials clearly demonstrate that
this is a promising strategic target for breast cancer
therapy. There is no doubt that antiprogestins in combina-
tion with other hormones/antihormones of proven antitu-
mor effects such as tamoxifen, and inhibitors of ras, Src
or MAPK will find their way into the routine treatment of
breast cancer.
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